Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00104130

Enrollment

Registered

2005-02-24

Start date

2004-12-31

Completion date

2005-02-28

Last updated

2008-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

prostate

Brief summary

The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.

Detailed description

This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.

Interventions

DRUGKOS-862

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* At least 18 years of age. * Metastatic disease. * One previous treatment including docetaxel (Taxotere). * At least 3 weeks since last surgery/radiation/chemotherapy * ECOG Performance Status of 0, 1 or 2

Exclusion criteria

* Active brain metastases

Design outcomes

Primary

Measure	Time frame
prostate cancer	—
prostate-specific antigen (PSA) response	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026